Physician profile
David A Baum
NPI 1245296888
$3,547.03
in general payments reported to CMS, 2019-2025
28 companies · $616 in 2025
The $616 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $217 · 2021: $474 · 2022: $507 · 2023: $646 · 2024: $646 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,347.33 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $334.93 | 2019-2025 | Myosure Tissue Removal Device, Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Pfizer INC. | $302.38 | 2021-2024 | |
| Coopersurgical, INC. | $226.07 | 2022-2025 | Endosee, Paragard T 380a |
| Organon LLC | $203.71 | 2023-2025 | Jada System, Nexplanon |
| Exeltis, USA INC. | $117.12 | 2020-2025 | Slynd |
| Dysis Medical, INC. | $115.29 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.39 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $97.63 | 2023-2025 | |
| Allergan, INC. | $86.22 | 2019-2020 | |
| Biogen, INC. | $77.25 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $58.24 | 2024-2025 | Veozah |
| Therapeuticsmd, INC. | $57.06 | 2019-2020 | |
| Avion Pharmaceuticals | $54.08 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $52.08 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $51.83 | 2019 | |
| Shield Therapeutics INC | $42.25 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $36.66 | 2019-2024 | Gardasil 9, Gardasil |
| Lupin INC. | $32.95 | 2019-2020 | |
| Becton, Dickinson and Company | $21.62 | 2024 | Bd Onclarity |
| Agile Therapeutics, INC. | $21.15 | 2024 | Twirla |
| Millicent US INC | $20.92 | 2025 | Intrarosa |
| Cytyc Surgical Products, LLC | $18.97 | 2025 | Myosure Tissue Removal Device |
| Gynesonics, INC. | $18.17 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Sumitomo Pharma America, INC. | $17.09 | 2024 | Myfembree |
| Ascend Therapeutics US, LLC | $12.70 | 2023 | |
| Smith+Nephew, INC. | $11.94 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.